companiesCompany

Johnson & Johnson

aka Alza Corporation, Janssen, Ortho Biotech Products, L.P., Ortho Biotech, Sequus Pharmaceuticals, Centocor, Inc., Centocor, Alza Corporation, DE, USA, Cougar Biotechnology, Inc., Cougar Biotechnology, McNeil Consumer & Specialty Pharmaceuticals, McNeil

Johnson & Johnson leads in multiple myeloma (Darzalex, Carvykti, Tecvayli, Talvey) and in bispecific antibodies for lung cancer (Rybrevant).

Johnson & Johnson, based in New Brunswick, New Jersey, and listed as JNJ, leads in multiple myeloma with Darzalex, Carvykti, Tecvayli and Talvey and in bispecific antibodies for lung cancer with Rybrevant. Its oncology portfolio spans daratumumab, teclistamab, talquetamab, ciltacabtagene autoleucel developed with Legend, amivantamab with lazertinib, abiraterone and apalutamide in prostate cancer, TAR-200 intravesical gemcitabine for bladder cancer approved in 2025, and pasritamig, a KLK2 by CD3 bispecific. Nuclide links it to the CARTITUDE-1 and CARTITUDE-4, MAIA, CEPHEUS and MajesTEC-1 papers, to the LEGEND-2 trial, to robotic bronchoscopy, and to the Yale Open Data Access project. Whether CAR-T and bispecifics move into first-line myeloma and displace daratumumab combinations is the question its own portfolio poses. Teclistamab, cilta-cel and amivantamab have their own pages.

Headquarters

New Brunswick, NJ, US

Scorecard

All companies

#12of 90 companies, score 52

approved products +6
phase 3 +3
targets +2
modalities +4
regions +7
registry trials +30

1 approved, 1 in phase 3, 0 earlier, 1 targets, 221 registry studies. Formula on the about page.

Financial snapshot, FY2024

Total revenue: $88.8bn
R&D spend: $17.2bn

Darzalex $11.7bnErleada $3.0bnImbruvica $2.9bnCarvykti $1.0bn

Company totals include MedTech. J&J reports an Oncology franchise within Innovative Medicine; the aggregate is not repeated here. Johnson & Johnson Form 10-K, FY2024 (SEC EDGAR)

Manufacturing

Capacity map

Legend Biotech and Janssen Raritan Raritan, New Jersey, US · Legend Biotech with Johnson & Johnson
Cell therapy
Legend Biotech Ghent (Tech Lane) Ghent, BE · Legend Biotech with Johnson & Johnson
Cell therapy

Type

pharma · JNJ

Stage

Public

Website

www.jnj.com

Products

2top

Phase 3costimulatory bispecific antibody (PSMA x CD28, per the sponsor's pipeline page)

JNJ-87189401

JNJ-87189401 is an experimental costimulatory agent from Janssen Research & Development in phase 3 trials for prostate cancer, aimed at PSMA.

ApprovedSmall-molecule CYP17A1 inhibitor

Abiraterone acetate · Zytiga (generic)

Abiraterone is a pill that shuts down testosterone production everywhere, including inside the tumour. Discovered at the Institute of Cancer Research, now generic and used from the first metastatic diagnosis.